GNOM vs HTEC
Global X Genomics & Biotechnology ETF against ROBO Global Healthcare Technology and Innovation ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
22%
14 shared positions
Fee gap
18 bp
GNOM is cheaper
1-year return gap
30.0 pts
GNOM is ahead
Larger fund
GNOM
$101M
Side by side
| GNOM | HTEC | |
|---|---|---|
| Fund | Global X Genomics & Biotechnology ETF | ROBO Global Healthcare Technology and Innovation ETF |
| Issuer | Global X | ROBO |
| Category | Biotech & Health Innovation | Biotech & Health Innovation |
| Expense ratio | 0.50% | 0.68% |
| Assets | $101M | $74M |
| Average daily dollar volume | $2.8M | $2.5M |
| Listed | Apr 5, 2019 | Jun 24, 2019 |
| FrenzyCap score | 50 | 43 |
| 1-month return | +10.9% | +6.5% |
| 3-month return | +23.6% | +13.2% |
| Year to date | +51.2% | +21.8% |
| 1-year return | +63.4% | +33.4% |
| 30-day volatility | 38.5% | 22.8% |
| Worst drawdown, 1 year | −18.2% | −16.3% |
| Trailing 12-month yield | 0.94% | 0.81% |
| Holdings | 52 | 62 |
| Top 10 weight | 55.9% | 22.6% |
| Look-through P/E | — | 84.0 |
| Holdings vs fair value | −2.4% | −0.9% |
| Holdings above 200-day average | 77% | 62% |
| Net flow, latest 3 reported months | +$1.4M thru May 2026 | +$7.6M thru Jul 2026 |
| 30-day implied volatility | 39.0% | 24.7% |
| Holdings as of | as of Oct 9, 2026issuer data | as of Apr 30, 2026SEC filing |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
53% of GNOM · 25% of HTEC
Sector mix of the stock holdings
| Sector | GNOM | HTEC | Gap |
|---|---|---|---|
| Health Care | 79.4% | 61.8% | +17.6% |
| Technology | 15.0% | 12.7% | +2.4% |
| Industrials | 0.0% | 1.7% | −1.7% |
More: full overlap table · GNOM holdings · HTEC holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.